Company Filing History:
Years Active: 2016-2018
Title: Innovations of Craig Johnstone
Introduction
Craig Johnstone is an accomplished inventor based in Abingdon, GB. He has made significant contributions to the field of biopharmaceuticals, particularly in the modulation of TNF activity. With a total of three patents to his name, Johnstone's work is pivotal in addressing various human ailments.
Latest Patents
Johnstone's latest patents include "Fused imidazole and pyrazole derivatives as modulators of TNF activity." This patent describes a series of substituted benzimidazole, imidazo[1,2-a]pyridine, and pyrazolo[1,5-a]pyridine derivatives that serve as potent modulators of human TNFα activity. These compounds are beneficial in the treatment and prevention of autoimmune and inflammatory disorders, neurological and neurodegenerative disorders, pain and nociceptive disorders, cardiovascular disorders, metabolic disorders, ocular disorders, and oncological disorders. Another notable patent is "Substituted imidazo[1,2-a]pyrazines as TNF activity modulators." This patent outlines a series of imidazo[1,2-a]pyrazine derivatives that also act as potent modulators of human TNFα activity, providing similar therapeutic benefits.
Career Highlights
Johnstone is currently employed at UCB Biopharma Sprl, where he continues to innovate and develop new therapeutic solutions. His expertise in biochemistry and pharmacology has positioned him as a key player in the research and development of novel treatments.
Collaborations
Throughout his career, Johnstone has collaborated with notable colleagues, including Jonathan Bentley and Daniel Christopher Brookings. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Craig Johnstone's contributions to the field of biopharmaceuticals through his patents and collaborations highlight his commitment to advancing medical science. His work continues to have a significant impact on the treatment of various human ailments.